ComplianceOnline

Drafting a Software V&V Documentation Package and Protocol

Instructor: John E Lincoln
Product ID: 704848
  • 11
  • January 2017
    Wednesday
  • 10:00 AM PST | 01:00 PM EST
    Duration: 90 Min

Live Online Training
January 11, Wednesday 10:00 AM PST | 01:00 PM EST
Duration: 90 Min

$199.00
One Dial-in One Attendee
$399.00
Group-Max. 10 Attendees/Location
(For multiple locations contact Customer Care)

recorded version

$249.00
1x Person - Unlimited viewing for 6 Months
(For multiple locations contact Customer Care)
Recorded Link and Ref. material will be available in My CO Section 48 hrs after completion of Live training

Training CD

$299.00
One CD is for usage in one location only.
(For multiple locations contact Customer Care)
CD and Ref. material will be shipped within 15 business days after completion of Live training

Customer Care

Fax: +1-650-963-2556

Email: customercare@complianceonline.com

Read Frequently Asked Questions

A tougher U.S. FDA expects a company to maintain certain documents in equipment, process and product software V&V. These documentation requirements can assist in a 21 CFR Part 11 CGMP records / signature V&V as well. This training program will provide valuable assistance to all regulated companies in evaluating their existing or anticipated software V&V activities and documentation requirements, especially in light of the changes in the FDA's stance vis a vis industry compliance, past problems, and the growing cloud environment. It will help attendees understand and recognize the most common software V&V failings and their fixes. The webinar will allow attendees to develop and use a repeatable software V&V template for all software validation projects.

Why Should You Attend:

Software and related hardware design, development, verification and validation is difficult to manage, document and control. This presentation will focus on the documentation required by the U.S. FDA for the verification and validation planning and execution of software after basic developmental testing and de-bug. It includes COTS (commercial off-the-shelf) and growing cloud-based software.

A suggested field-tested 11-element FDA model will be evaluated, implemented, with V&V documentation and test case examples. The focus of the webcast is on the most recent issues the FDA has had in this area, and remediation approaches. Software considered: 1) In-product, 2) As-product, 3) Production and test, and 4) QMS / 21 CFR Pt. 11. Field examples, good and bad will be addressed. Evaluation of the chief areas of FDA concerns will focus on actual and anticipated changes in emphasis based on the changing regulatory climate.

Areas Covered in the Webinar:

  • Major industry failures
  • Tougher FDA expectations / requirements
  • Roles of verification and validation
  • The 11-element FDA model - and where it's required
  • A typical software V&V protocol / test report
  • A brief overview of 21 CFR Part 11, ER / ES
  • Legacy, hybrid, new, and cloud systems
  • Expected regulatory deliverables
  • Complementary guidelines, e.g., GAMP

Who Will Benefit:

This information applies to personnel / companies in the pharmaceutical, medical device, diagnostic, nutraceutical and biologics fields. Employees who will benefit include:

  • Senior management
  • Regulatory affairs
  • Quality assurance / QAE
  • Production
  • Engineering
  • R&D
  • Software development and testing teams
  • All personnel involved in a U.S. FDA-regulated environment
  • Those involved in new product development with products and equipment that are software driven
  • Companies with quality management / MRP / ERP systems moving toward paperless systems or other regulated medical products activities
Instructor Profile:
John E Lincoln

John E Lincoln
Principal, J E Lincoln and Associates

John E. Lincoln is principal of J. E. Lincoln and Associates LLC, a consulting company, with over 33 years’ experience in U.S. FDA-regulated industries and 20 years as a full-time consultant. He has worked with companies from start-up to Fortune 100, in the U.S., Mexico, Canada, France, Germany, Sweden, China and Taiwan.

He specializes in quality assurance, regulatory affairs, QMS problem remediation and FDA responses, new / changed product 510(k)s, process/ product/ equipment including QMS and so+E6ftware validations, ISO 14971 product risk management files / reports, design control / design history files, and technical files. He's held positions in manufacturing engineering, QA, QAE, regulatory affairs, to the level of director and VP (R&D). In addition, Mr. Lincoln has prior experience in military, government, electronics, and aerospace. He has published numerous articles in peer reviewed journals, conducted workshops and webinars worldwide on CGMP subjects. He is a graduate of UCLA.

Topic Background:

Software/ firmware design and development is under increased scrutiny by the new tougher U.S. FDA. Recently a major pharma company paid a $750 M fine for poor compliance, and software V&V was one of the key contributors.

Product, production/ test equipment, and even the QMS are heavily software/ firmware driven in today's manufacturing. A comprehensive, corporate wide plan is a necessity. Growing cloud issues add urgency to upgrade control. Software's complex logic pathways mandate resource-intensive V&V activities, in a resource-constrained environment. Risk-based software documentation is the answer. What are the best approaches for companies to take? How can tougher FDA expectations be met? What V&V is necessary to minimize software failures in the field or in-house? How to bring software V&V in under budget and within project timelines?

Follow us :
ComplianceOnline Banking Summit 2016 | Risk Management and Data Security - 80390SEM
ComplianceOnline Medical Device Summit 2017

Product Reviews

This product hasn't received any reviews yet. Be the first to review this product! Write review

Best Sellers
You Recently Viewed
    Loading